Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

We recently compiled a list of the Billionaire Ken Fisher’s Top 10 High Growth Stock Picks. In this article, we are going to ...

The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

If you're looking for cheap growth stocks to buy, three you'll want to consider today are Novo Nordisk ( NVO 3.76%), Carnival ...